Effects of α-substitutions on structure and biological activity of anticancer chalcones

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 22, 2006, Pages 5844-5848

  Lawrence, Nicholas J ^a,b   Patterson, Richard P ^b   Ooi, Li Ling ^b   Cook, Darren ^c   Ducki, Sylvie ^c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF SALFORD   (United Kingdom)

Author keywords

Anticancer; Chalcone; Fluorination; Fluorine; Tubulin

Indexed keywords

ANTINEOPLASTIC AGENT; CHALCONE; TUBULIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CELL LINE; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG EFFECT; FLUORINATION; HUMAN; HUMAN CELL; IC 50; MITOSIS; POLYMERIZATION; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANTIMITOTIC AGENTS; ANTINEOPLASTIC AGENTS; CHALCONE; HUMANS; K562 CELLS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUMOR CELLS, CULTURED;

EID: 33749609344     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.08.065     Document Type: Article

References (26)

1. Hsieh H.K., Lee T.H., Wang J.P., Wang J.J., and Lin C.N. Pharm. Res. 15 (1998) 39
2. Li R.S., Kenyon G.L., Cohen F.E., Chen X.W., Gong B.Q., Dominguez J.N., Davidson E., Kurzban G., Miller R.E., Nuzum E.O., Rosenthal P.J., and McKerrow J.H. J. Med. Chem. 38 (1995) 5031
3. Nielsen S.F., Boesen T., Larsen M., Schonning K., and Kromann H. Biorg. Med. Chem. Lett. 12 (2004) 3047
4. Ducki S., Forrest R., Hadfield J.A., Kendall A., Lawrence N.J., McGown A.T., and Rennison D. Biorg. Med. Chem. Lett. 8 (1998) 1051
5. Edwards M.L., Stemerick D.M., and Sunkara P.S. J. Med. Chem. 33 (1990) 1948
6. Kumar S.K., Hager E., Pettit C., Gurulingappa H., Davidson N.E., and Khan S.R. J. Med. Chem. 46 (2003) 2813
7. Go M.L., Wu X., and Liu X.L. Curr. Med. Chem. 12 (2005) 483
8. Pettit G.R., Singh S.B., Hamel E., Lin C.M., Alberts D.S., and Garciakendall D. Experientia 45 (1989) 209
9. Ohsumi K., Hatanaka T., Nakagawa R., Fukuda Y., Morinaga Y., Suga Y., Nihei Y., Ohishi K., Akiyama Y., and Tsuji T. Anti-Cancer Drug Des. 14 (1999) 539
10. Davis P.D., Dougherty G.J., Blakey D.C., Galbraith S.M., Tozer G.M., Holder A.L., Naylor M.A., Nolan J., Stratford M.R.L., Chaplin D.J., and Hill S.A. Cancer Res. 62 (2002) 7247
11. Tozer G.M., Kanthou C., and Baguley B.C. Nat. Rev. Cancer 5 (2005) 423
12. Li Q., and Sham H.L. Exp. Opin. Ther. Pat. 12 (2002) 1663
13. Lawrence N.J., Hepworth L.A., Rennison D., McGown A.T., and Hadfield J.A. J. Fluorine Chem. 123 (2003) 101
14. Isanbor C., and O'Hagan D. J. Fluorine Chem. 127 (2006) 303
15. Boehm H.-J., Banner D., Bendels S., Kansy M., Kuhn B., Mueller K., Obst-Sander U., and Stahl M. ChemBioChem 5 (2004) 637
16. Ismail F.M.D. J. Fluorine Chem. 118 (2002) 27
17. Lawrence N.J., McGown A.T., Ducki S., and Hadfield J.A. Anti-Cancer Drug Des. 15 (2000) 135
18. The crystals for X-ray analysis were prepared by the diffusion method between methanol and a solution of the substrate in chloroform. CCDC 617654 and 617653 contain the supplementary crystallographic data for 6c and 8c respectively. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via http://www.ccdc.cam.ac.uk/data_request/cif.
19. 19F NMR δ (283 MHz; CDCl(3))
20. Balaji B.S., and Chanda B.M. Tetrahedron 54 (1998) 13237
21. Goldsmith D.J. J. Org. Chem. 26 (1961) 2078
22. Nam N., Kim Y., You Y., Hong D., Kim H., and Ahn B. Bioorg. Med. Chem. Lett. 11 (2001) 3073
23. Fujii T., Yoshifuji S., and Yamada K. Tetrahedron Lett. 16 (1975) 1527
24. Currie D.J., and Holmes H.L. Can. J. Chem. 47 (1969) 863
25. Tret'yak S.M., Yarmolenko S.N., Fialkov Y.A., and Yagupol'skii L.M. Zh. Org. Khim. 25 (1989) 1950
26. Fletcher D.A., McMeeking R.F., and Parkin D. J. Chem. Inf. Comp. Sci. 36 (1996) 746